Advertisement

Breast Cancer

, Volume 8, Issue 3, pp 194–201 | Cite as

Prognostic value of p53 protein expression in breast cancer; An immunohistochemical analysis of frozen sections in 514 Japanese women

  • Shinichi Tsutsui
  • Shinji Ohno
  • Shigeru Murakami
  • Yoichi Hachitanda
  • Shinya Oda
Original Article

Abstract

Background

Although the prognostic value of p53 protein has been extensively studied in breast cancer, there have so far been few immunohistochemical studies of p53 protein using frozen sections in a large series of Japanese women with breast cancer.

Patients and methods

Immunohistochemical staining for p53 protein was performed on frozen sections from 514 Japanese patients with breast cancer with a mean follow-up duration of 31 months.

Results

Two hundred and eight (40.5%) of 514 cases showed nuclear accumulation of p53 protein. There was a significant inverse correlation between p53 protein and estrogen receptor (ER) status. The patients who were positive for p53 protein had a significantly worse outcome in terms of both disease free survival (DFS) (p<0.0001) and overall survival (OS) (p=0.0411) than those negative for p53 protein. The same effect on DFS was seen in subgroups divided either by nodal status or ER status. Multivariate analyses indicated that nodal status, ER and p53 protein were all independent prognostic factors for DFS. The nodal status, ER and tumor size were independent prognostic factors for OS, and p53 protein status was still an independent prognostic factor for DFS in subgroups divided either by nodal status or ER status.

Conclusion

Our findings demonstrated the prognostic value of p53 protein expression for the early recurrence of breast cancer, and the prognostic value of p53 protein expression was independent from that of both the nodal status and ER status in breast cancer.

Keywords

p53 Immunohistochemistry Prognosis Breast cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Hollstein M, Sidransky D, Vogelstein B,et al: p53 mutations in human cancers.Science 253: 49–53, 1991.PubMedCrossRefGoogle Scholar
  2. 2).
    Elledge RM, Fuqua SAW, Clark GM,et al: William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer.Breast Cancer Res Treat 27: 95–102, 1993.PubMedCrossRefGoogle Scholar
  3. 3).
    Lane DP, Benchimol S: p53: oncogene or anti-oncogene?Genes Dev 4: 1–8, 1990.PubMedCrossRefGoogle Scholar
  4. 4).
    Finlay CA, Hinds PW, Tan TH,et al: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.Mol Cell Biol 8: 531–539, 1988.PubMedGoogle Scholar
  5. 5).
    Prioleau J, Schnitt SJ: p53 antigen loss in stored paraffin slides.N Engl J Med 332: 1521–1522, 1995.PubMedCrossRefGoogle Scholar
  6. 6).
    Hurlimann J: Prognostic value of p53 protein expression in breast carcinomas.Pathol Res Pract 189: 996–1003, 1993.PubMedGoogle Scholar
  7. 7).
    Davidoff AM, Herndon II JE, Glover NS,et al: Relation between p53 overexpression and established prognostic factors in breast cancer.Surgery 110: 259–264, 1991.PubMedGoogle Scholar
  8. 8).
    Allred DC, Clark GM, Elledge R,et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.J Natl Cancer Inst 85: 200–206, 1993.PubMedCrossRefGoogle Scholar
  9. 9).
    Stenmark-Askmalm M, Stal O, Olsen K,et al: p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.Br J Cancer 72: 715–719, 1995.PubMedGoogle Scholar
  10. 10).
    Silvestrini R, Daidone MG, Benini E,et al: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers.Clin Cancer Res 2: 2007–2013, 1996.PubMedGoogle Scholar
  11. 11).
    Charpin C, Garcia S, Bouvier C,et al: Quantitative immunocytochemical assays on frozen sections of p53: correlation to the follow-up of patients with breast carcinomas.Am J Clin Pathol 106: 640–646, 1996.PubMedGoogle Scholar
  12. 12).
    Elledge RM, Clark GM, Fuqua SAW,et al: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.Cancer Res 54: 3752–3757, 1994.PubMedGoogle Scholar
  13. 13).
    Walker RA, Dearing SJ, Lane DP,et al: Expression of p53 protein in infiltrating and in-situ breast carcinomas.J Pathol 165: 203–211, 1991.PubMedCrossRefGoogle Scholar
  14. 14).
    Thor AD, Moore II DH, Edgerton SM,el al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.J Natl Cancer Inst 84: 845–855, 1992PubMedCrossRefGoogle Scholar
  15. 15).
    Isola J, Visakorpi T, Holli K,et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor porgnosis in nodenegative breast cancer patients.J Natl Cancer Inst 84: 1109–1114, 1992.PubMedCrossRefGoogle Scholar
  16. 16).
    Barnes DM, Dublin EA, Fisher CJ,et al: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?Hum Pathol 24: 469–476, 1993.PubMedCrossRefGoogle Scholar
  17. 17).
    Gasparini G, Weidner N, Bevilacqua P,et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.J Clin Oncol 12: 454–466, 1994.PubMedGoogle Scholar
  18. 18).
    MacGrogan G, Bonichon F, de Mascarel I,et al: Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.Breast Cancer Res Treat 36: 71–81, 1995.PubMedCrossRefGoogle Scholar
  19. 19).
    Silvestrini R, Benini E, Veneroni S,et al: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.J Clin Oncol 14: 1604–1610, 1996.PubMedGoogle Scholar
  20. 20).
    Sjogren S, Inganas M, Norberg T,et al: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.J Natl Cancer Inst 88: 173–182, 1996.PubMedCrossRefGoogle Scholar
  21. 21).
    Fresno M, Molina R, Perez del Rio MJ,et al: p53 expression is of independent predictive value in lymph node-negative breast carcinoma.Eur J Cancer 33: 1268–1274, 1997.PubMedCrossRefGoogle Scholar
  22. 22).
    Bosari S, Lee AKC, Viale G,et al: Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up.Virchows Arch A Pathol Anat Histopathol 421: 291–295, 1992.PubMedCrossRefGoogle Scholar
  23. 23).
    Cunningham JM, Ingle JN, Jung SH,et al: p53 gene expression in node-positive breast cacner: relationship to DNA ploidy and prognosis.J Natl Cancer Inst 86: 1871–1873, 1994.PubMedCrossRefGoogle Scholar
  24. 24).
    Rosen PP, Lesser ML, Arroyo CD,et al: p53 in nodenegative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.J Clin Oncol 13: 821–830, 1995.PubMedGoogle Scholar
  25. 25).
    Haerslev T, Jacobsen GK: An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis.Hum Pathol 26: 295–301, 1995.PubMedCrossRefGoogle Scholar
  26. 26).
    Reed W, Hannisdal E, Boehler PJ,et al: The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.Cancer 88: 804–813, 2000.PubMedCrossRefGoogle Scholar
  27. 27).
    Elledge RM, Allred DC: Prognostic and predictive value of p53 and p21 in breast cancer.Breast Cancer Res Treat 52: 79–98, 1998.PubMedCrossRefGoogle Scholar
  28. 28).
    Le Marchand L: Ethnic variation in breast cancer survival: a review.Breast Cancer Res Treat 18: S119–126, 1991.PubMedCrossRefGoogle Scholar
  29. 29).
    Merchant WJ, Millis RR, Smith P,et al: Expression of c-erbB2 and p53 protein is similar in breast cancer from British and Japanese women.Int J Cancer 84: 278–283, 1999.PubMedCrossRefGoogle Scholar
  30. 30).
    Iwaya K, Tsuda H, Fukutomi T,et al: Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer.Jpn J Clin Oncol 27: 6–12, 1997.PubMedCrossRefGoogle Scholar
  31. 31).
    Takikawa Y, Noguchi M, Kitagawa H,et al: Immunohistochemical detection of p53 and c-erbB-2 proteins: prognostic significance in operable breast cancer.Breast Cancer 1: 17–23, 1994.CrossRefGoogle Scholar
  32. 32).
    Zhang GJ, Tsuda H, Adachi I,et al: Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.Jpn J Clin Oncol 27: 371–377, 1997.PubMedCrossRefGoogle Scholar
  33. 33).
    Kato T, Kimura T, Miyakawa R,et al: Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer.Br J Cancer 82: 404–411, 2000.Google Scholar
  34. 34).
    Bruner JM, Connelly JH, Saya H: p53 protein immunostaining in routinely processed paraffin-embedded sections.Mod Pathol 6: 189–194, 1993.PubMedGoogle Scholar
  35. 35).
    Brambilla E, Gazzeri S, Moro D,et al: Immunohistochemical study of p53 in human lung carcinomas.Am J Pathol 143: 199–210, 1993.PubMedGoogle Scholar
  36. 36).
    Davidoff AM, Kerns BJ, Iglehart JD,et al: Maintenance of p53 alterations throughout breast cancer progression.Cancer Res 51: 2605–2610, 1991.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2001

Authors and Affiliations

  • Shinichi Tsutsui
    • 1
  • Shinji Ohno
    • 1
  • Shigeru Murakami
    • 1
  • Yoichi Hachitanda
    • 2
  • Shinya Oda
    • 3
  1. 1.Department of Breast SurgeryNational Kyushu Cancer CenterJapan
  2. 2.Department of PathologyNational Kyushu Cancer CenterJapan
  3. 3.Institute for Clinical ResearchNational Kyushu Cancer CenterJapan

Personalised recommendations